APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 217 filers reported holding APELLIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.07 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42,431,718 | +57.5% | 1,115,450 | +277.2% | 0.65% | +36.9% |
| Q2 2023 | $26,940,456 | -50.3% | 295,724 | -64.0% | 0.48% | -54.4% |
| Q1 2023 | $54,153,160 | +758.4% | 821,000 | +573.0% | 1.05% | +968.4% |
| Q4 2022 | $6,308,620 | +42.1% | 122,000 | +87.7% | 0.10% | +60.7% |
| Q3 2022 | $4,439,000 | -87.8% | 65,000 | -90.9% | 0.06% | -86.0% |
| Q1 2022 | $36,278,000 | +63.3% | 714,000 | +51.9% | 0.44% | +74.4% |
| Q4 2021 | $22,220,000 | -40.2% | 470,000 | -58.3% | 0.25% | -41.2% |
| Q3 2021 | $37,167,000 | +33.5% | 1,127,643 | +156.0% | 0.42% | +16.8% |
| Q2 2021 | $27,839,000 | +1147.8% | 440,500 | +747.1% | 0.36% | +658.3% |
| Q1 2021 | $2,231,000 | +23.4% | 52,000 | -13.3% | 0.05% | +14.3% |
| Q3 2020 | $1,808,000 | +1155.6% | 60,000 | +1011.1% | 0.04% | +425.0% |
| Q1 2020 | $144,000 | -95.5% | 5,400 | -94.9% | 0.01% | -92.6% |
| Q4 2019 | $3,227,000 | – | 105,400 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |